title: Assessment of quality of life in the treatment of major depressive disorder with fluoxetine, 20 mg, in ambulatory patients aged over 60 years.
authors.affiliation: Eli Lilly Benelux SA, Brussels, Belgium.
authors.forename: P
authors.initials: P
authors.lastname: Mesters
authors.forename: P
authors.initials: P
authors.lastname: Cosyns
authors.forename: G
authors.initials: G
authors.lastname: Dejaiffe
authors.forename: J
authors.initials: J
authors.lastname: Fanielle
authors.forename: C
authors.initials: C
authors.lastname: Gilles
authors.forename: J
authors.initials: J
authors.lastname: Godderis
authors.forename: J
authors.initials: J
authors.lastname: Grégoire
authors.forename: N
authors.initials: N
authors.lastname: de Leval
authors.forename: P
authors.initials: P
authors.lastname: Meire
authors.forename: F
authors.initials: F
authors.lastname: Mesotten
mesh_terms: D000368:Aged; D000553:Ambulatory Care; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D015577:Geriatric Assessment; D006801:Humans; D008297:Male; D008875:Middle Aged; D010555:Personality Inventory; D011788:Quality of Life
chemical_list: D005473:Fluoxetine